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Peripheral blood dendritic cells seem to play a crucial role in psoriatic inﬂammatory processes. The aim of our study is to inves-
tigate the relationship between plasma interleukin-18 (IL-18) levels and blood dendritic cells in psoriatic patients. IL-18 plasma
levels were measured by ELISA. Phenotypes of dendritic cell subsets were analyzed by double-colour ﬂow cytometry. Plasma IL-
18 level in psoriatic males was signiﬁcantly higher, whereas counts of BDCA-2+ cells were lower than in the control group. The
myeloid/plasmacytoidratiowassigniﬁcantlyhigherinthepatientgroupcomparedtothecontrolone.Inthepatientgroup,signiﬁ-
cant negative correlations between plasma IL-18 level and both the BDCA-1+ and BDCA-2+ counts were found. BDCA-1+ counts
correlated negatively with percentage of skin involvement. IL-18 seems to play a role in psoriasis pathogenesis. The decreased
counts of blood plasmacytoid DCs in psoriatic patients might result from IL-18 down-regulation of plasmacytoid DC precursor
proliferation.
Copyright © 2007 Aldona Pietrzak et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Interleukin-18 (IL-18) is produced by a wide range of cells,
primarily macrophages, monocytes, and to a smaller degree
by keratinocytes and osteoblasts [1]. It strengthens cytotoxic
properties of natural killer (NK) cells and CD8+ T cells.
It also possesses a unique ability to increase the activity of
both Th1-type as well as Th2-type CD4+ T cells and de-
pends on local cytokine network [2]. IL-18 contributes to
inﬂammation and fever due to its potent inducing eﬀects
on the gene expression and synthesis of interferon-γ (IFN-
γ),granulocyte-macrophagecolony-stimulatingfactor(GM-
CSF), tumour necrosis factor (TNF), interleukin-1 (IL-1),
fas ligand (FasL), and several chemokines [3–7]. Being a
pleiotropic cytokine, IL-18 can play an immunoregulatory
role,especiallyininﬂammatory,infectious,andautoimmune
diseases.
Only a few studies analysed the role of IL-18 in psoria-
sis vulgaris [4, 8–10], they did not, however, yield conclusive
results [11]. Increased expression of IL-18 was demonstrated
in keratinocytes from psoriatic lesions in comparison to ker-
atinocytes from normal skin [12–15]. However, neither the
bioactivity of IL-18 nor the inﬂuence of IFN-γ on inﬂam-
matory processes in the peripheral blood mononuclear cells
(PBMC) from psoriatic scales could be detected [12]. The
level of IL-18 mRNA was demonstrated to be 2- to 8-fold
higher in extracts from psoriatic skin lesions than the one
obtained from both uninvolved skin extracts in psoriasis pa-
tients and healthysubjects. Similarly, 6- to8-fold highercon-
c e n t r a t i o n so fI L - 1 8r e c e p t o r sm R N Aw e r eo b s e r v e di np s o -
riatic lesional skin in comparison to both uninvolved skin of
psoriasis patients and healthy subjects [13–15].
In the human peripheral blood, two distinct lineages of
dendritic cells (DCs) were identiﬁed—myeloid and plasma-
cytoid dendritic cells (mDCs and pDCs, resp.) [16]. These
two subsets of DCs have been implicated in inducing diverse
types of immune responses, with mDCs favouring Th1- and
pDCs favouring Th2-type immune reactions proﬁle [17].2 Mediators of Inﬂammation
ThesetwoDCssubsetscanbedistinguishedbytheirdiﬀerent
surface antigens. mDCs express speciﬁc antigen-blood den-
dritic cell antigen BDCA-1, whereas pDCs express character-
istic antigen BDCA-2 [18].
Recent data indicate that DCs may be involved in patho-
logical processes in numerous diseases, including immune-
mediated skin conditions [19, 20]. In psoriasis, BDCA-2 cells
were detected in the basal layer of the epidermis and the pap-
illary dermis [20]. This observation is particularly interest-
ing in the context of the most important immunopathogenic
hypotheses of psoriasis focused on the synthesis and release
of proinﬂammatory mediators by activated DCs and T cells,
distorted function of the immune synapse leading to the
emergence of self-reactive T cells or epidermal expression of
chemokines attracting T cells and DCs into the skin [21].
Some studies suggested that DCs may be associated with
IL-18. Gutzmer et al. [22] have recently demonstrated that
human DCs express IL-18 receptors and that IL-18 has a di-
rect chemotactic eﬀect on DCs. Increased IL-18 levels, ob-
servedinsomediseases,mightleadtoDCsrecruitmenttothe
sites of inﬂammation. Companjen et al. [11] found that in
the epidermis, IL-18 expression was detected not only in ker-
atinocytes but also in the cells with a dendritic morphology,
probably Langerhans cells. The cellular inﬁltrate in the der-
mal papillae of psoriatic lesional skin, containing cells with
dendritic and lymphocyte morphology, also expressed IL-18.
Since several lines of evidence link the pathogenesis of
psoriasistobothincreasedlevelsofIL-18andDCsfunctions,
wedecidedtoinvestigatetherelationshipbetweenplasmaIL-
18andbloodDCsinpsoriasispatients.Wehypothesizedthat
such correlation may help to explain some of the pathogenic
processes observed in the psoriatic skin.
2. MATERIALS AND METHODS
2.1. Participants
Thirty-eight males with psoriasis and 21 healthy male vol-
unteers took part in the study. Patients were hospitalized at
DepartmentofDermatology,VenerologyandPaediatricDer-
matology,MedicalUniversityofLublin,Poland,duetopsori-
asis vulgaris. Patients had a chronic active type of psoriasis of
moderate severity with the mean psoriasis area and severity
index (PASI) of 24.56 ± 8.28 (M±SD) and the average per-
centage of skin involvement of 28.44 ± 19.54%. The severity
of psoriasis was evaluated in each patient by the same inves-
tigator. The mean duration of psoriasis calculated in months
was 152.10 ± 149.46. The patients treated with topical or
systemic steroids, any form of dithranol or retinoid therapy
prior to examination, were excluded from entering the study.
Subjectswith other systemic,infectious, parasitic, neurologi-
cal, or psychiatric diseases were also excluded from the study.
The blood samples were collected from all the participants
in the morning. The patients remained seated for at least
15 minutes prior to blood collection. An informed written
consent was obtained after complete description of the study
from each participant. The study was approved by the Ethics
Committee of the Medical University of Lublin.
2.2. EvaluationofDCssubpopulations
The mononuclear cells were isolated from heparinised blood
by density gradient centrifugation on Lymphoprep (Ny-
comed, Norway) and washed twice in phosphate buﬀered
saline without Ca2+ and Mg2+ containing 0.5% bovine
serum albumin and 2mM EDTA. The phenotypes of DCs
were analysed with double-colour ﬂow cytometry using
monoclonal antibodies: mouse antihuman BDCA-1-FITC
(Miltenyi-Biotec, Germany), CD19-CyChrome (Pharmin-
gen, USA), BDCA-2-FITC (Miltenyi-Biotec, Germany),
CD123-PE (Becton Dickinson, USA), and matched isotype
control (Caltag, USA). The cell staining was performed
according to the manufacturers’ instructions in the pres-
ence of FcR blocking reagent (Miltenyi-Biotec, Germany).
The immunolabelled cells were collected (a total of 300000
events) using an FACSCalibur ﬂow cytometer equipped with
488nm argon laser (Becton Dickinson) and analysed with
cell-quest software. The numbers of myeloid and plasmacy-
toid DCs were quantiﬁed as the percentages of peripheral
blood mononuclear cells. mDCs were deﬁned as BDCA-1
positive and simultaneously CD19 negative cells, whereas
pDCsasdoubleBDCA-2andCD123positivecells(Figure 1).
2.3. EvaluationofIL-18plasmaconcentration
Plasma IL-18 concentration was determined by a com-
mercially available Human IL-18 ELISA kit (MBL, Japan).
Plasma samples were collected on EDTA as anticoagulant
a n ds t o r e dd e e pf r o z e na t−80◦C until further evaluated. The
analytical procedure was performed according to the manu-
facturers’instructions.ELISAReaderElx800(BIO-TECKIn-
struments)wasusedfortheexamination.Thedetectionlimit
of Human IL-18 ELISA kit is 12.5pg/mL.
3. STATISTICAL ANALYSIS
Results are presented as mean, median, 25 percentile and 75
percentile, mean (M), standard deviation (SD). The ﬁt of the
data to the normal distribution was tested with Kolmogorov-
Smirnov test. Since the distribution of the data was signiﬁ-
cantly diﬀerent from normal, nonparametric statistics were
further used. Mann-Whitney U test was employed for com-
parison between patient and control groups, and Spearman
rho correlations coeﬃcients were calculated between the as-
sessed variables. A P value <.05 was considered statistically
signiﬁcant.
4. RESULTS
4.1. Groupcharacteristics
The patients and healthy controls were homogeneous with
respect to the number of demographic, physical, and be-
havioural variables including age, weight, height, body mass
index (BMI), blood pressure, WBC, frequency of smoking,
and declared alcohol intake (Table 1). None of the diﬀer-
ences between the patients and healthy subjects in the mean
values of these variables proved to be statistically signiﬁcant
(P<. 05).Aldona Pietrzak et al. 3
Table 1: Demographic, physical, and behavioural characteristics of patients with psoriasis and healthy controls.
Patients Healthy controls Mann-Whitney
U test
Mean Median 25 percentile 75 percentile Mean Median 25 percentile 75 percentile ZP
Age (years) 37.74 41.0 25.00 47.00 34.04 33.5 24.00 39.50 1.20 .22
Weight (kg) 78.12 77.0 68.00 86.00 78.47 77.0 71.50 86.50 −0.40 .68
Height (cm) 174.64 177.0 171.00 180.00 176.5 176.5 173.00 181.00 −0.84 .40
BMI (kg/m2) 25.60 25.24 22.22 27.45 25.38 25.06 23.27 28.00 0.05 .95
RR1 (mmHg) 129.58 120.0 120.00 140.00 125.7 125.0 120.00 132.50 0.66 .50
RR2 (mmHg) 83.51 80.0 75.00 90.00 82.54 80.0 80.00 85.00 0.24 .80
WBC (K/μL) 6.60 6.12 5.45 7.79 6.27 6.09 5.36 9.1 0.83 .40
Smoking
(number/day) 5.8 0 0 10.00 7.12 1.5 0.00 15.00 −0.44 .65
Alcohol consumption
(L/month) 0.61 0 0 0.50 0.74 0.25 0.10 0.70 −1.55 .12
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Figure 1: (a) Myeloid and plasmacytoid DCs were quantiﬁed as the percentages of peripheral blood mononuclear cells, (b) mDCs were
deﬁned as BDCA-1 positive and simultaneously CD19 negative cells, (c) pDCs as double BDCA-2 and CD123 positive cells. Correlations
between IL-18 and DCs in patients with psoriasis and healthy controls.
4.2. IL-18levelsandDCscountsinpatientsand
healthysubjects
The mean plasma level of IL-18 was signiﬁcantly increased in
males with psoriasis as compared to the healthy control male
group (P = .027). The counts of BDCA-1+ cells in psoriasis
patients werenot signiﬁcantlydiﬀerent fromthose in healthy
controls (P<. 05). The counts of BDCA-2+ cells were found
to be signiﬁcantly lower in patients with psoriasis than those
in healthy controls (P = .001). The myeloid/plasmacytoid
ratio was signiﬁcantly higher in psoriatic patients compared
to the control group (Figure 2).
4.3. CorrelationsbetweenIL-18andDCsinpatients
andhealthysubjects
In the correlations between IL-18 and BDCA-1+ cells,
BDCA-2+ cells were examined separately for the patient and4 Mediators of Inﬂammation
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Figure 2: Comparison between men with psoriasis and healthy subjects: (a) percentages myeloid BDCA-1+/CD19- DCs, (b) plasmacytoid
BDCA2+/CD123+ DCs, (c) myeloid/plasmacytoid ratio, and (d) blood concentration of IL-18. Results are shown as median values and
25–75 percentiles.
the control groups. In the latter, none of the correlation co-
eﬃcients was found to be statistically signiﬁcant. In the pa-
tient group, however, statistically signiﬁcant negative corre-
lations were found both between the BDCA-1+ cell counts
and plasma IL-18 level (rho =− 0.38) as well as the BDCA-
2+cellcountsandplasmaIL-18level(rho =− 0.41)(Table 2,
Figure 3).
4.4. CorrelationsbetweenIL-18,DCs,andclinical
severityofpsoriasispatients
In the patient group, correlation coeﬃcients were calculated
between the DCs subpopulations, IL-18, and clinical severity
ofthedisease.NeitherDCsnorIL-18showedstatisticallysig-
niﬁcant correlations with the severity of psoriasis expressedAldona Pietrzak et al. 5
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Figure 3: Correlations between IL-18 and DCs in patients with psoriasis and healthy controls.
by PASI score. IL-18 and BDCA-2+ did not demonstrate sta-
tistically signiﬁcant correlations with percentage of skin in-
volvement in psoriatic patients either. However, the sever-
ity of the disease, expressed by percentage of skin involve-
ment correlated negatively with BDCA-1+ cell counts (rho =
−0.39) (Table 3).
5. DISCUSSION
Our patients with psoriasis showed signiﬁcantly increased
levelsofplasmaIL-18ascomparedtohealthysubjects,which
conﬁrms ﬁndings reported by other authors [4], and our
previous ones [8–10]. Increased IL-18 levels found in our6 Mediators of Inﬂammation
Table 2: Spearman rho correlation coeﬃcients between IL-18 and
DCs in patients with psoriasis and healthy controls. Correlations
marked by asterisk are statistically signiﬁcant with P<. 05.
IL-18
Patients Controls
BDCA-1+/CD19- rho −0.38∗ −0.33
BDCA-2+/CD123+ rho −0.41∗ 0.07
Myeloid/plasmacytoid ratio rho −0.008 −0.31
Table 3: Spearman rho correlation coeﬃcients between IL-18,
DCs, and clinical characteristics of psoriasis in patients with psoria-
sis. Correlations marked by asterisk are statistically signiﬁcant with
P<. 05.
PASI Lesional skin (%)
IL-18 rho 0.071 0.26
BDCA-1+/CD19- rho −0.17 −0.39∗
BDCA-2+/CD123+ rho −0.07 −0.02
Myeloid/plasmacytoid
ratio rho −0.16 −0.38∗
patients seem to be in agreement with the widely accepted
observation that IL-18 is a potent inducer of IFN-γ from
T cells, NK cells, B cells, dendritic cells and, generally, is a
trigger of the Th1 immune response [11, 23]. Taking into
account the fact that psoriasis is a Th1-type disease, IL-18
m a yb er e g a r d e dt ob eo fs o m ei m p o r t a n c ei ni t sp a t h o g e n -
esis. This is further supported by studies demonstrating de-
creaseofIL-18levelsafternarrowbandUVBtherapytogether
with other parameters’ characteristics for Th1 response [24].
Apart from stimulating the Th1 response, IL-18 can regu-
late the Th2 response depending on local cytokine network.
IL-12 enhances IFN-γ production induced by IL-18, whereas
IL-18 alone induces IL-4 and IL-13 production [23, 25].
These unique properties of IL-18 could explain statisti-
cally signiﬁcant negative correlations between the BDCA-1+
cellcountsandplasmaIL-18levelaswellastheBDCA-2+cell
counts and plasma IL-18 level. Kaser et al. [26] showed that
plasmacytoidDClineageexpressanαchainofIL-18receptor
(IL-18Rα). Therefore, IL-18 can directly down-regulate pro-
liferation of plasmacytoid DC precursors (pre-DC2s). This,
in turn, can lead to a decrease in BDCA-2+ cells. IFN-γ
was demonstrated to up-regulate the IL-18R on monocyte-
derived dendritic cells [22, 27]. It might have the similar ef-
fect on dendritic cells in vivo. Our results show the statisti-
cally signiﬁcant decrease of BDCA-2+ cells and the signiﬁ-
cantly higher myeloid/plasmacytoid ratio in the psoriatic pa-
tients compared to the control group. Spearman’s rank cor-
relation coeﬃcients indicated that negative correlation be-
tween IL-18 and BDCA-2+ is more pronounced (Figure 3).
This ﬁnding could be explained by both the direct inﬂuence
ofIL-18onplasmacytoidDCs,whichinpsoriasisisenhanced
byincreasedlevelofIL-12[24],aswellasadditionalfunction
of IL-4. The Th2-type cytokine-IL-4 is able to induce apop-
tosis of plasmacytoid DCs, but IFN-γ can protect BDCA-2+
cells from this process [28].
Nestle et al. [29] observed a lower level of BDCA-2+
cells in the blood of psoriatic patients than in healthy sub-
jects.TheysuggestedthatBDCA-2+cellsaredecreasedinthe
blood of psoriatic patients due to their migration into the le-
sional skin, a phenomenon similar to that observed in sys-
temic lupus erythematosus. Therefore, the decreased counts
of BDCA-2+ cells we found in our patients might possibly
be related to their presumed migration into the lesional skin.
This remains in agreement with the ﬁndings of other authors
who observed increased DCs counts in the lesional psoriatic
skin [20, 29].
Nestle et al. [29] found an elevated level of plasmacytoid
DCs in both plaque lesions and uninvolved skin of psoriatic
patients as compared to the skin of control subjects. Kaser
et al. [26] analysed the role of IL-18 in the initial phase of
Th response and demonstrated that IL-18 interacts with the
diﬀerentiation pathway of plasmacytoid DCs. Through this
modulation, IL-18 shifts the Th1/Th2 balance towards Th1
response. The potent chemotactic activity of IL-18 on plas-
macytoid DCs was also identiﬁed. Further studies are, how-
ever, required to examine the chemotactic eﬀect of IL-18 on
plasmacytoid DCs in the psoriatic patients’ skin and blood.
What is more is that investigation on the expression of IL-
18R on plasmacytoid DCs in the patients’ skin and blood
seems to be of considerable usefulness.
The counts of BDCA-1+ cells were not signiﬁcantly dif-
ferent in the blood of our psoriatic patients from that of
healthy controls. However, our study demonstrated a signif-
icant negative correlation (rho =− 0.38) between plasma
IL-18 and BDCA-1+ cell counts in patients with psoriasis.
This negative correlation may be the result of myeloid den-
dritic cell downregulation driven by IFN-γ, as it was already
demonstrated in systemic lupus erythematosus [30]. In con-
clusion, based on the increased IL-18 levels in plasma of our
patients, this cytokine seems to play a role in the etiopatho-
genesis of psoriasis which was already suggested by many
authors. Decreased blood plasmacytoid DCs in psoriatic pa-
tients might be related to the IL-18 down-regulation of plas-
macytoid DC precursor proliferation. IFN-γ, by exerting its
inﬂuence on myeloid/plasmacytid ratio, on the one hand
coulddown-regulatemyeloiddendriticcellsandontheother
hand can protect plasmacytoid dendritic cells from apopto-
sis. Explanation of the exact mechanisms of interactions be-
tween IL-18 and DCs in psoriasis requires, however, further
studies.
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